Gedatolisib Doublet, Triplet Regimens Improve PFS in Patients With PIK3CA Wild-Type HR+/HER2– Breast Cancer - Prabadin Corp

Email

weborders@prabadincorp.com

Call us

+1 (786)-332-3938

Gedatolisib Doublet, Triplet Regimens Improve PFS in Patients With PIK3CA Wild-Type HR+/HER2– Breast Cancer

Health

July 30, 2025

By AdminPrabadin - 6 days ago

0

Emerging trial results reveal gedatolisib significantly enhances progression-free survival (PFS) in advanced HR+/HER2- breast cancer.

administrator